SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Sun Pharmaceutical Industries rises as its arm incorporates wholly-owned subsidiary

06 Feb 2024 Evaluate

Sun Pharmaceutical Industries is currently trading at Rs. 1468.50, up by 4.60 points or 0.31% from its previous closing of Rs. 1463.90 on the BSE.

The scrip opened at Rs. 1463.50 and has touched a high and low of Rs. 1470.40 and Rs. 1450.00 respectively. So far 13171 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 1,472.00 on 06-Feb-2024 and a 52 week low of Rs. 922.55 on 22-May-2023.

Last one week high and low of the scrip stood at Rs. 1472.00 and Rs. 1367.75 respectively. The current market cap of the company is Rs. 351958.45 crore.

The promoters holding in the company stood at 54.48%, while Institutions and Non-Institutions held 36.59% and 8.92% respectively.

Sun Pharmaceutical Industries’ subsidiary -- Taro Pharmaceutical Industries has incorporated wholly-owned subsidiary company with the name ‘Taro Pharma Corporation, Inc.’ (USA) on February 5, 2024. Taro Pharma Corporation is set up as an entity separate from Alchemee LLC, a subsidiary of Taro Israel, to help Alchemee LLC with selling its Proactiv skincare products on e-commerce marketplace in USA.

Sun Pharmaceutical Industries is among the largest specialty generic pharmaceutical company and India's top pharmaceutical company.

Sun Pharma Inds. Share Price

1675.20 -17.95 (-1.06%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×